Home  »  Trending   »  Looking Closely at the Growth Curve for Summit The...

Looking Closely at the Growth Curve for Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Inc. (NASDAQ:SMMT) went down by -8.15% from its latest closing price compared to the recent 1-year high of $6.54. The company’s stock price has collected -6.06% of loss in the last five trading sessions.

Is It Worth Investing in Summit Therapeutics Inc. (NASDAQ :SMMT) Right Now?

Plus, the 36-month beta value for SMMT is at 0.93.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $4.00. SMMT currently public float of 33.89M and currently shorts hold a 1.04% ratio of that float. Today, the average trading volume of SMMT was 2.04M shares.

SMMT’s Market Performance

SMMT stocks went down by -6.06% for the week, with a monthly drop of -23.93% and a quarterly performance of 14.81%, while its annual performance rate touched -80.86%. The volatility ratio for the week stands at 12.72% while the volatility levels for the past 30 days are set at 12.75% for Summit Therapeutics Inc. The simple moving average for the period of the last 20 days is -2.09% for SMMT stocks with a simple moving average of -35.42% for the last 200 days.

Analysts’ Opinion of SMMT

Needham gave a rating of “Buy” to SMMT, setting the target price at $27 in the report published on April 12th of the previous year.

SMMT Trading at 9.19% from the 50-Day Moving Average

After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.04% of loss for the given period.

Volatility was left at 12.75%, however, over the last 30 days, the volatility rate increased by 12.72%, as shares sank -18.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.61% upper at present.

During the last 5 trading sessions, SMMT fell by -6.06%, which changed the moving average for the period of 200-days by -75.20% in comparison to the 20-day moving average, which settled at $1.2520. In addition, Summit Therapeutics Inc. saw -53.90% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at SMMT starting from DUGGAN ROBERT W, who purchase 94,849,203 shares at the price of $0.97 back on Aug 16. After this action, DUGGAN ROBERT W now owns 162,532,792 shares of Summit Therapeutics Inc., valued at $92,003,727 using the latest closing price.

Zanganeh Maky, the Co-CEO & President of Summit Therapeutics Inc., purchase 5,624,702 shares at $0.97 during a trade that took place back on Aug 16, which means that Zanganeh Maky is holding 7,061,557 shares at $5,455,961 based on the most recent closing price.

Stock Fundamentals for SMMT

Equity return is now at value -112.70, with -74.70 for asset returns.

Is Cadence Bank (CADE) a Keeper?

Cadence Bank (NYSE:CADE) went down by -0.52% from its latest closing price compared to the recent 1-year high of $34.24. The company’s stock price has